This is my last post from #ASCO22. It includes a variety of Tweets dealing with studies from the meeting I found interesting.
Though geared toward GU Cancers similar integrative efforts could apply to Gyn cancers too. #gyncsm #ASCO22— Dee Sparacio (@womenofteal) June 6, 2022
Slide 25 "What do Patients Want to Know?"
Excellent Presentation @birensaraiya https://t.co/rCxSn9LQos
Using Claims-based Data
Larissa Meyer, MD, MPH, on an Algorithm to Find Incident Epithelial Ovarian Cancer #gyncsm— Dee Sparacio (@womenofteal) June 6, 2022
algorithm will facilitate research in other claims-based data sets where cancer registry data are unavailable.https://t.co/G8sdaBn5ch
"Use of chemo is increasing while radiation therapy is decreasing" in stage II-III uterine #leiomyosarcoma. "Radiation is associated w/ improved survival in stage II and III, while there was no association between adjuvant chemo & survival in stage II." #sarcoma #gyncsm https://t.co/HdEkSdCZXl— Suzie Siegel (@SuzieSiegel) June 6, 2022
✅ For White patients, incidence of disease matches enrollment.— Erika Hamilton, MD (@ErikaHamilton9) June 6, 2022
👎 For Black and Hispanic patients, incidence much higher than trial participation.
🔆Trials need to reflect the population we are treating! 🔆#bcsm #ASCO22 @OncoAlert #clinicaltrials @DrRFreedman pic.twitter.com/sD4w5aQmuf
Cascade Testing and ovarian cancer
Genetic testing innovation in #ovariancancer. Pilot study by Frey MK et al. found 53% success of cascade testing when clinical team directly contacted relatives for cancer family history vs. 36% when responsibility was left to patients #gyncsm #ASCO22 pic.twitter.com/W7Otlu5RLG— Allegra Rollo (@AllegraRollo) June 6, 2022
Rare cancer treatments
Excited to hear Dr Jyoti Mayadev speak about “Novel Radiosensitizers in Cervical, Vaginal, and Vulvar Cancers” at #ASCO22 on ways to optimize outcomes with chemoRT for #gyncsm. Nice to see a #womenWhoCurie on stage @ASCO pic.twitter.com/qKDmsCGe7I— Fumiko Ladd Chino, MD (@fumikochino) June 6, 2022
Thanks for joining me as I reviewed ASCO research. I hope to see you at ASCO next year.
Every Day is a Blessing!